Scientific article
Review
English

Chemotherapeutic options in the management of anal cancer

Published in

Expert opinion on pharmacotherapy, vol. 5, no. 12, p. 2479-2484

Publication date

2004

Abstract

During the past two decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumours; so far, it remains one of the few carcinomas of the gastrointestinal tract which are curable without the need for definitive surgery. Since the original contribution by Nigro in 1974, surprisingly few changes have been made to the standard of care in chemotherapy, which still consists of a combination of 5-fluorouracil and mitomycin C. However, many issues have yet to be clarified, such as the potential role of cisplatin as a substitute to mitomycin, as well as treatment-induced toxicity in HIV-positive patients. In this paper, the management of patients with anal cancer is presented, and new chemotherapeutic options are critically reviewed. Finally, the authors' opinion regarding currently unresolved issues in the treatment of these rare neoplasms is expressed.

Keywords

  • Anus Neoplasms/therapy
  • Carcinoma, Squamous Cell/complications/therapy
  • Cisplatin/therapeutic use
  • Combined Modality Therapy
  • Fluorouracil/therapeutic use
  • HIV Seropositivity/complications
  • Humans
  • Mitomycin/therapeutic use

Citation (ISO format)

GERVAZ, Pascal et al. Chemotherapeutic options in the management of anal cancer. In: Expert opinion on pharmacotherapy, 2004, vol. 5, n° 12, p. 2479–2484. doi: 10.1517/14656566.5.12.2479

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1465-6566
785views
0downloads

Technical informations

Creation

11/11/2014 15:46:00

First validation

11/11/2014 15:46:00

Update

14/03/2023 22:14:20

Status update

14/03/2023 22:14:20

Last indexation

30/10/2024 20:41:35
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated